Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 4, 2022
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
Tue, May 3, 2022
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
[ Tue, May 03rd 2022
] - WOPRAI
Vamil Divan Maintained (AXSM) at Strong Buy with Decreased Target to $49 on, May 3rd, 2022
Vamil Divan of Mizuho, Maintained "Axsome Therapeutics, Inc." (AXSM) at Strong Buy with Decreased Target from $51 to $49 on, May 3rd, 2022.
Vamil has made no other calls on AXSM in the last 4 months.
There are 3 other peers that have a rating on AXSM. Out of the 3 peers that are also analyzing AXSM, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Wednesday, April 27th, 2022
These are the ratings of the 2 analyists that currently disagree with Vamil
- Chris Howerton of "Jefferies" Maintained at Strong Buy with Increased Target to $77 on, Tuesday, March 29th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 2nd, 2022
